|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The recent surge in next generation sequencing (NGS) technology has shed more light on the genetic landscape of SBCLs through characterization of numerous driver mutations including SF3B1 and NOTCH1 in CLL, ATM and CCND1 in MCL, KMT2D and EPHA7 in FL, MYD88 (L265P) in LPL, KLF2 and NOTCH2 in splenic MZL (SMZL) and BRAF (V600E) in HCL.
|
27121112 |
2016 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Sensitive molecular assays for detecting BRAF V600E allow HCL (highly responsive to purine analogs) to be better distinguished from HCL-like disorders, which are treated differently.
|
27554081 |
2016 |
|
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
The recent application of high-throughput sequencing to NHL not only advances the understanding of disease pathogenesis and classification, but allows the discovery of new drug targets, such as BRAF gene inhibition in hairy cell leukemia.
|
27910030 |
2017 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
HCL variant and the IGHV4-34 molecular variant of HCL lack BRAF mutation and have inferior outcomes with standard purine analogue therapy.
|
28146266 |
2017 |
|
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Patients' leukemic cells exposed ex vivo to BRAF inhibitors are spoiled of their HCL identity and then undergo apoptosis.
|
28297625 |
2017 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of 3 or 4 based on the CD11C, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral medullary infiltration and the presence of BRAF V600E somatic mutation.
|
29110361 |
2017 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In order to investigate the suitability of MinION sequencing on formalin-fixed paraffin-embedded samples, the presence and frequency of BRAF c.1799T > A mutation was investigated in two archival tissue specimens of Hairy cell leukemia and Hairy cell leukemia Variant.
|
29238890 |
2018 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Many such genetic events have already demonstrated clinical utility, such as BRAF V600E that confers sensitivity to vemurafenib in patients with hairy cell leukemia.
|
29702524 |
2018 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Hairy cell leukemia (HCL) is a rare, low-grade mature B-cell neoplasm with a characteristic clinical, morphological, immunophenotypic, and more recently described molecular (BRAF p.V600E mutation) profile.
|
30197362 |
2018 |
|
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
To the best of our knowledge, this is the first case of a co-occurring BRAF positive melanoma and HCL to be reported in a chemotherapy-naïve patient.
|
30680261 |
2018 |
|
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expert opinion: Ongoing and planned studies will help to optimize the use of BRAF inhibitor therapy for HCL by determining the efficacy of BRAF inhibition in combination with other antigen targeted or molecularly targeted therapies, and more broadly, to determine how hematologists can best utilize and sequence emerging diagnostic and therapeutic modalities in the care of patients with newly diagnosed and relapsed or refractory HCL.
|
30782032 |
2019 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Identification of the BRAF-V600E kinase mutation as the genetic cause of HCL has opened the way, in the relapsed/refractory experimental setting, to targeted and non-myelotoxic effective strategies that are based on inhibition of BRAF with vemurafenib, co-inhibition of BRAF and its target MEK with dabrafenib and trametinib, and BRAF inhibition with vemurafenib combined with anti-CD20 immunotherapy.
|
31187521 |
2019 |
|
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
An overview of the major forms of treatment of HCL (cytostatic drugs, specific BRAF inhibitors, B cell-specific antibodies) is given.
|
31282776 |
2019 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The intestinal lymphoma bears the BRAF V600E mutant, which is the molecular hallmark of HCL, being implicated in its pathogenesis.
|
31354304 |
2019 |
|
Hairy Cell Leukemia
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutation of BRAF V600E was pronounced in HCL, but "hairiness" was not linked to the mutation.
|
31538423 |
2019 |
|
Hairy Cell Leukemia
|
0.600 |
Biomarker
|
disease |
BEFREE |
IMPLICATIONS FOR PRACTICE: Hairy cell leukemia (HCL) has effective treatments including purine analogs with and without rituximab, and oral inhibitors of BRAF, MEK and Bruton's tyrosine kinase (BTK).
|
31628266 |
2020 |